Navigating the Patient Journey in Chronic Lymphocytic Leukemia: Oncology Nurse Strategies in Therapy Management

May 20, 2021

Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors. There will also be discussion on strategies to optimize patient satisfaction and communication by addressing clinical challenges, promotion of patient adherence, proper management of adverse events, and the encouragement of open communication between provider and patient. This educational initiative will be interactive, with attendees following the patient journey through real-world patient cases and polling questions incorporated throughout.


Presented by Creative Educational Concepts, Inc.

Supported through an independent educational grant from AstraZeneca.

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Learning Objectives

  • Review the role of the BCR (B-cell receptor) pathway in CLL development and examine currently available and emerging novel therapies targeting the BCR pathway.
  • Appraise the appropriate selection and sequencing of CLL therapy based on current guideline recommendations and patient-specific factors such as line and duration of therapy, clinical presentation, mutation status, among others.
  • Discuss unique differences between novel therapies, strategies to properly monitor and manage toxicities, and key counseling points to discuss with patients to ensure minimization of toxicities and optimization of oral adherence.
  • Explore strategies to ensure patient understanding and empowerment about their treatment plan and ways to encourage open communication between patient and provider to optimize outcomes.

Additional Information

AttachmentSize
PDF icon Handout and References2.82 MB
PDF icon CEC Zoom Guide448.5 KB
Course summary
Available credit: 
  • 1.00 ANCC
    • 0.75 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
04/26/2021
Course expires: 
06/20/2021
Event starts: 
05/20/2021 - 6:00pm
Event ends: 
05/20/2021 - 7:30pm
Rating: 
0

5 min

Welcome and Introductions/Pre-test

10 min

Exploring the BCR Pathway in Chronic Lymphocytic Leukemia: Novel Therapies at the Forefront

40 min

Collaborative Decision-Making and Optimization of Patient Outcomes in CLL: Patient Cases for the Oncology Nurse

5 min

Conversations with the Experts and Q&A/Post-test

Live Virtual Event
Tennessee Valley ONS
6:00PM EDT Chapter Meeting
6:30PM EDT Presentation
United States

Katherine L. Byar, MSN, ANP-BC, BMTCN
Oncology Nurse Practitioner
University of Nebraska Medical Center
Omaha, Nebraska

 


Katherine Byar, MSN, APRN-BC, BMTCN® is a nurse practitioner in oncology at Nebraska Medicine where she provides care to oncology patients, both inpatient and outpatient.  Her passion is caring for patients with hematological malignancies; along with educating and mentoring other healthcare providers related to this area.

She received her Bachelor of Science in Nursing from Nebraska Methodist College in Omaha and Master of Science in Nursing at the University of Nebraska Medical Center. She is certified as an ANP-BC from ANCC and a Bone Marrow Transplant Certified Nurse (BMTCN) from Oncology Nursing Society (ONS).

She is currently a co-editor for ONS Cancer Basics Edition 3 textbook. She has written several book chapters, co-authored numerous articles and posters and has lectured extensively on a variety of oncology related topics. She is an active member of ONS, ASPHO, ASCO, and NNP. Currently, she is the nurse practitioner representative for ASCO Editorial Board, Nebraska Nurse Practitioner Nominating Committee Chair-Elect and serves as a member on the APSHO Communications Committee. 

 

Matthew Lunning, DO
Associate Professor, Internal Medicine
UNMC Hematology/Oncology Division
Nebraska Medical Center
Omaha, Nebraska

 

Matthew Lunning D.O., FACP, is an Associate Professor in the Division of Hematology/Oncology and is the Associate Vice Chair of Research for the Department of Internal Medicine and Medical Director of the Clinical Research Center (CRC).

He received his medical degree from Des Moines University in 2006. Dr. Lunning completed his Internal Medicine residency at UNMC where he served as Chief Medical Resident. He completed his Hematology/Oncology fellowship and served as the Hematology Chief Fellow at Memorial Sloan-Kettering Cancer Center. Dr. Lunning returned to UNMC in 2013 and been active in clinical research, research mentoring, education, and patient care. Dr. Lunning was the recipient of the Distinguish Scientist Award in 2019.

Dr. Lunning has served on several National Comprehensive Cancer Network’s guideline committees including the Immunotherapy Toxicity & T-cell lymphoma panels. He has served as an invited member of ASCO’s Cancer Education Committee on the Non-Hodgkin Lymphoma. Additionally, he is the co-organizer of the Pan Pacific Lymphoma Conference.


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:  
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Katherine L. Byar, MSN, ANP-BC, BMTCN–has no relevant financial relationships to disclose in relation to the content of this activity.

Matthew Lunning, DO–has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.
 
Authors/Presenters:
Katherine L. Byar, MSN, ANP-BC, BMTCN–has no relevant financial relationships to disclose in relation to the content of this activity.

Ian W. Flinn, MD, PhD–has disclosed that he is a consultant for AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx Pharma, and Yingli Pharmceuticals but his honorarium is issued to his institution, Sarah Cannon Research Institute. He receives grant/research support from AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, and Verastem but his honorarium is issued to his institution, Sarah Cannon Research Institute.

Amy L Goodrich, RN, MSN, CRNP-AC–has disclosed that she is a consultant/on the advisory board for Abbvie, AstraZeneca, Celgene, and Rigel.

Matthew Lunning, DO–has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.

Shazia K. Nakhoda, MD–has no relevant financial relationships to disclose in relation to the content of this activity.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC–has disclosed that she is a consultant for ADCC Therapeutics, Cardinal Health, and Coherus. She is on the speakers' bureau for AstraZeneca and Coherus.

Julie Vose, MD, MBA–has disclosed that she is a consultant for Abbvie, Acerta Pharma/AstraZeneca, Conjupro Biotherapeutics, Genentech, Janssen/Pharmacyclics, Johnson and Johnson, Kite Pharma, Morphyosis, Oncternal, Roche, and Vaniam Group. She receives grant/research support from Acerta Pharma/AstraZeneca, Celgene/BMS, Epizyme, Incyte Corp., Kite Pharma, LOXO, Novartis, and Seattle Genetics, Inc.

Reviewer:
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of an evaluation and credit request, statements of credit for nurses will be issued automatically.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.0 point in Care Continuum, Care of the Pediatric Hematology and Oncology Patient, Diagnosis and Staging, Disease-Related Biology, Oncologic Emergencies, Oncology Nursing Practice, Quality of Life, Psychosocial, Scientific Basis for Practice, Survivorship, Symptom Management, and Treatment categories. 

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. 

Available Credit

  • 1.00 ANCC
    • 0.75 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Please login or register to take this course.